Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aims</h3><p>The prostate transmembrane protein, androgen induced 1 (PMEPA1) is differentially expressed in pan-cancer. However, PMEPA1 specific role in cancers has not been fully clarified. This study aims to explore the potential role of Pmepa1 in pan-cancer and specific cancer, with a view to deepening the research on the pathological mechanism of cancer.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Main methods</h3><p>The Perl language and R language were used to identify the correlation between PMEPA1 expression level and clinical indicators, prognosis values, tumor microenvironment, immune cells' infiltration, immune checkpoint genes, TMB and MSI. The Therapeutic Target Database was used for identifying potential therapeutic drugs that target the pathways that are significantly affected by PMEPA1 expression.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Key findings</h3><p>PMEPA1 differential expression significantly correlated with patients' age, race, tumors' stage and status. PMEPA1 high expression was closely correlated with poor prognosis in many cancer types, excluding prostate adenocarcinoma. PMEPA1 expression was closely related to tumor cells and the immune microenvironment in stromal and immune cells' level, immune cells' infiltration, immune checkpoint genes, tumor mutational burden and microsatellite instability. We also found that the activity of the olfactory transduction pathway was closely related to PMEPA1 expression. In pan-cancer, Trifluoperazine and Halofantrine have the potential to reduce PMEPA1 expression.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Significance</h3><p>This study integrated existing data to explore PMEPA1 potential function in cancers, provided insights for the future cancer-related studies.</p>

PMEPA1 Induces EMT Via a Non‐canonical TGF‐β Signalling in Colorectal Cancer

[Transmembrane Prostate Androgen-Induced Protein 1 (PMEPA1) Promotes the Migration and Maintains Mesenchymal-Like Phenotype of Breast Cancer Cells].

PMEPA1 Is a Prognostic Biomarker That Correlates With Cell Malignancy and the Tumor Microenvironment in Bladder Cancer

Gdf15 Promotes Emt And Metastasis In Colorectal Cancer

MTA1 Promotes Metastasis of MPM Via Suppression of E-cadherin

TMEPAI regulates EMT in lung cancer cells by modulating the ROS and IRS-1 signaling pathways.

The molecular mechanism of transforming growth factor-β1-induced transmembrane protein participating in the development of breast cancer

Diagnostic and therapeutic values of PMEPA1 and its correlation with tumor immunity in pan-cancer

PRMT5 Promotes Epithelial‐mesenchymal Transition Via EGFR‐β‐catenin Axis in Pancreatic Cancer Cells

MAEL Expression Links Epithelial‐mesenchymal Transition and Stem Cell Properties in Colorectal Cancer

The Integrated Pathway of TGFβ/Snail with TNFα/NFκB May Facilitate the Tumor-Stroma Interaction in the EMT Process and Colorectal Cancer Prognosis.

PMEPA1 interference activates PTEN/PI3K/AKT, thereby inhibiting the proliferation, invasion and migration of pancreatic cancer cells and enhancing the sensitivity to gemcitabine and cisplatin

Phorbol Ester Phorbol‐12‐myristate‐13‐acetate Induces Epithelial to Mesenchymal Transition in Human Prostate Cancer ARCaPE Cells

PEA15 Promotes Liver Metastasis of Colorectal Cancer by Upregulating the ERK/MAPK Signaling Pathway.

A TGF-β-MTA1-SOX4-EZH2 signaling axis drives epithelial–mesenchymal transition in tumor metastasis

Tumour Microenvironment: a Non-Negligible Driver for Epithelial−mesenchymal Transition in Colorectal Cancer

Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway

The Clinical Significance of the Expression Level of PMEPA1 in Prostate Cancer

Metalloproteases Meprin-Ɑ (MEP1A) is a Prognostic Biomarker and Promotes Proliferation and Invasion of Colorectal Cancer

Loss of PPM1A Expression Enhances Invasion and the Epithelial-to-mesenchymal Transition in Bladder Cancer by Activating the TGF-β/Smad Signaling Pathway

Prostate specific membrane E, a novel spliced variant of prostate-specific membrane antigen, regulates bone metastasis of prostate cancer cells